MA-PATHAI
21.5.2024 09:01:26 CEST | Business Wire | Press release
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for laboratories in the United States, which attracted over 50 laboratories with many exploring long-term use of PathAI’s AISight Image Management System and broad menu of AI Products.
As part of the EAP, AP Laboratories in Europe can trial AISight, a modern and cloud-based digital pathology solution compliant with GDPR, as well as conduct and publish real-world validation studies of PathAI’s AI Products such as ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1, and AIM-HER2.2
“We are thrilled to commence a more dedicated focus to bring AISight Image Management System to labs in Europe. We have continued to make improvements on the platform with input from our first set of commercial customers in the U.S. We are excited to partner with European labs in democratizing access to digital pathology, enhancing pathologist experience, and ultimately improving patient outcomes,” said Nick Brown, Chief Growth Officer at PathAI.
AISight is a cloud-based platform that enables efficient end-to-end digital pathology workflows. AISight provides best-in-class caseload balancing and assignment, caselist prioritization, image ingestion, image viewing, collaboration tools, and image and case management. Via AISight Link, AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflows. Anatomic pathology laboratories of all sizes and specialties – including health systems, university hospitals, and reference laboratories – may utilize AISight.
“PathAI has been an excellent thought partner for helping our institution think through what it means to create a modern, next-generation digital pathology workflow that spans versatile use cases like research, clinical trials, and diagnostics,” said Prof. Dr. Jan Budczies, Head of Medical Bioinformatics at the University of Heidelberg. “We are excited to partner with PathAI on this Early Access Program and look forward to taking advantage of their growing portfolio of features and algorithms on AISight, starting with our Molecular Pathology Department where we are especially interested in understanding the feasibility of estimating tumor cell content and characterizing immune cell infiltrates more precisely by leveraging digital pathology and artificial intelligence.”
AISight enables pathologists with seamless access to a broad array of algorithms to drive workflow optimization, standardized biomarker quantitation, and next-generation case prioritization including ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1 (NSCLC, HNSCC, Melanoma, Urothelial), and AIM-HER2 Breast Cancer and will also host third-party algorithms on request.
“We have trialed AISight at our department for several months now. At our Molecular Pathology Unit we are especially interested in understanding the feasibility of estimating tumor cell content through image analysis. PathAI’s AIM-TumorCellularity can be a tool that will change time to treatment for patients in need of molecular testing,” said Prof. Dr. Holger Moch, Director of Pathology at the University of Zurich and PathAI Advisor. “PathAI has been responsive to our unique needs and a valuable thought partner in helping us think through how to pick the most modern and innovative digital pathology solution on the market. We are excited about our partnership with PathAI and look forward to taking advantage of their growing portfolio of algorithms and feature improvements on AISight.”
“We have been leveraging the AIM-PD-L1 NSCLC and AIM-TumorCellularity NSCLC Algorithms over the past few months at our institution as part of a large research cohort,” said Dr. Jose Palacios, Director of Pathology at Ramon y Cajal Hospital in Madrid, Spain. “Given the success we’ve seen at our own institution, there has been increasing demand from across Spain to leverage these algorithms and we are working with more than 10+ hospitals across Spain to implement these tools.”
PathAI expects IVDR Certification of AISight Dx for primary diagnosis by Q3 2024. Early Access Program Participants will be the first to receive access to this platform. To learn more about AISight, visit our website. PathAI’s team will also be at upcoming conferences including the European Congress of Digital Pathology in Vilnius, Lithuania (June 5-8), European Congress of Pathology in Florence, Italy (September 7-11), and the DP/AI Congress in London, United Kingdom (December 7-8).
Footnotes
1 AISight™ is for research use only. Not for use in diagnostic procedures.
2 ArtifactDetect™, TumorDetect™, AIM-TumorCellularity™, AIM-PD-L1™ and AIM-HER2™ are research use only. Not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.
PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521660078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 15:00:00 CEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 15:00:00 CEST | Press release
First deployment scheduled to enter service in 2026, combining industrial-scale infrastructure, proprietary inference software and long-term customer commitments. Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That m
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 15:00:00 CEST | Press release
Partnership brings PCI-validated P2PE and tokenization into 934’s connected hospitality payment infrastructure Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization fo
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness30.9.2026 14:59:00 CEST | Press release
Completed three-year PROTECT randomized controlled trial finds NaturalVue Multifocal 1 Day contact lens slowed myopia progression by 1.06 diopters and eye elongation by 0.58 mm at 36 months.1,2 Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational randomized controlled trial evaluating the company's NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens for slowing the progression of myopia, or nearsightedness, in children. Ashley Tuan, OD, MS, PhD, VTI's Chief Medical Officer, will present the full findings at the American Academy of Optometry's annual meeting in Anaheim. Myopia develops when a child's eye grows too long, causing distant objects to appear blurry, and it typically worsens through childhood. Faster progression is associated with a higher lifelong risk of more serious eye conditions, including retinal detachmen
Lyft App Launches in Europe30.9.2026 14:00:00 CEST | Press release
North American riders can use their Lyft app when traveling in Europe Key takeaways: North American Lyft riders can now use one app in the U.S., Canada, and Europe. No need to download anything new. New technology allows the Lyft app to integrate any third-party marketplace, laying the groundwork for future international growth. Lyft has transformed from an everyday rideshare company into a global, multi-mobility platform. Starting today, Lyft (NASDAQ: LYFT) riders can use their Lyft app in cities across Europe. Early access to the Lyft app rolls out in Barcelona and Hamburg first; throughout October, the Lyft app will become available for riders to use in some of Europe’s largest cities including London, Rome, Paris, Berlin, Athens, and Warsaw. By the end of October riders visiting Spain, Italy, Greece, Poland, England, Scotland, Ireland, Austria, France, and Germany will have one go-to app when they cross the Atlantic, building on the foundations from this past summer beta testing th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom